These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 16848334

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical response to ertapenem in severe community-acquired pneumonia: a retrospective series in an elderly population.
    Murcia JM, González-Comeche J, Marín A, Barberán J, Granizo JJ, Aguilar L, González-Moreno J, González-Pina B, López-Dupla M, Irurzun J, SCAPE Study Group.
    Clin Microbiol Infect; 2009 Nov; 15(11):1046-50. PubMed ID: 19548926
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
    Frei CR, Restrepo MI, Mortensen EM, Burgess DS.
    Am J Med; 2006 Oct; 119(10):865-71. PubMed ID: 17000218
    [Abstract] [Full Text] [Related]

  • 7. A teaching hospital's experience applying the Pneumonia Severity Index and antibiotic guidelines in the management of community-acquired pneumonia.
    Lee RW, Lindstrom ST.
    Respirology; 2007 Sep; 12(5):754-8. PubMed ID: 17875067
    [Abstract] [Full Text] [Related]

  • 8. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 9. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar 15; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients.
    Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB.
    Respir Med; 2006 Dec 15; 100(12):2129-36. PubMed ID: 16730170
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
    Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR.
    Am J Med; 2006 Jun 15; 119(6):512.e1-7. PubMed ID: 16750965
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The pneumonia severity index and the CRB-65 in cancer patients with community-acquired pneumonia.
    Aliberti S, Brock GN, Peyrani P, Blasi F, Ramirez JA, Community-Acquired Pneumonia Organization.
    Int J Tuberc Lung Dis; 2009 Dec 15; 13(12):1550-6. PubMed ID: 19919775
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.